Piper Sandler Has Lowered Expectations for Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) had its price objective cut by investment analysts at Piper Sandler to $3.00 in a report released on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock.

MIST has been the subject of a number of other research reports. Wall Street Zen raised Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. HC Wainwright reissued a “buy” rating on shares of Milestone Pharmaceuticals in a research note on Thursday, September 3rd. Cantor Fitzgerald started coverage on Milestone Pharmaceuticals in a research note on Thursday, August 20th. They set an “overweight” rating and a $3.00 price target on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $5.83.

Check Out Our Latest Report on Milestone Pharmaceuticals

Milestone Pharmaceuticals Trading Up 13.2%

NASDAQ MIST opened at $0.41 on Monday. The firm’s fifty day moving average price is $0.77 and its two-hundred day moving average price is $1.29. The company has a quick ratio of 7.92, a current ratio of 6.27 and a debt-to-equity ratio of 3.25. Milestone Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Milestone Pharmaceuticals had a negative return on equity of 435.88% and a negative net margin of 1,860.76%. The company had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $1.00 million. As a group, sell-side analysts forecast that Milestone Pharmaceuticals will post -0.83 earnings per share for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several large investors have recently modified their holdings of MIST. RVW Wealth LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter valued at $994,000. Guardian Wealth Advisors LLC NC raised its position in Milestone Pharmaceuticals by 21.1% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock worth $455,000 after purchasing an additional 59,200 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in Milestone Pharmaceuticals during the 1st quarter worth $397,000. TRU Independence Asset Management 2 LLC acquired a new position in Milestone Pharmaceuticals during the 2nd quarter worth about $201,000. Finally, Valeo Financial Advisors LLC lifted its holdings in Milestone Pharmaceuticals by 12.2% during the 3rd quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock worth $127,000 after buying an additional 16,000 shares during the period. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

(Get Free Report)

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.

Further Reading

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.